Advertisement
Takeda
Subscribe to Takeda

The Lead

Takeda Forms Takeda Oncology to Commercialize Cancer Medicines

December 8, 2014 8:37 am | News | Comments

Takeda Pharmaceutical Company Limited announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients.

GE Healthcare and Takeda to Develop Therapeutic Drugs to Target Liver Diseases

November 11, 2014 8:13 am | News | Comments

GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an...

Sucampo Announces Extension of AMITIZA License and Collaboration Agreement With Takeda

October 14, 2014 9:08 am | News | Comments

Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration...

FDA Approves VELCADE® for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

October 9, 2014 1:48 pm | News | Comments

Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company...

View Sample

FREE Email Newsletter

Takeda Appoints New Head of Vaccine Development

October 8, 2014 8:41 am | News | Comments

Takeda Pharmaceuticals International has announced that John Boslego, MD, has been named Senior Vice President and Head of Development for Takeda’s Global Vaccine Business Unit, effective December 1, 2014.        

Court Orders Takeda to Pay $6B Over Actos Diabetes Drug

September 4, 2014 10:51 am | News | Comments

Takeda Pharmaceutical has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda's diabetes medicine Actos.       

FDA Approves VELCADE® Retreatment in Patients with Multiple Myeloma

August 11, 2014 8:19 am | News | Comments

Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, has announced that the FDA has approved VELCADE® for the retreatment of adult patients with multiple myeloma who had previously responded to VELCADE therapy and relapsed at least six months following completion of prior VELCADE treatment.

Advertisement

Takeda President: Company to Extend Global Reach Through Acquisitions

August 7, 2014 8:37 am | News | Comments

New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.   

Can Shareholders Stop a Company From Going Global?

June 27, 2014 8:53 am | Videos | Comments

A group of shareholders, led by Yujiro Hara, opposes the hiring of foreign executives at Takeda Pharmaceutical, the biggest drug company in Japan, calling it a “hijacking by foreign capital.”          

MacroGenics and Takeda to Develop DART for Treatment of Autoimmune Disorders

May 27, 2014 9:14 am | News | Comments

MacroGenics and Takeda jointly announced today that they have entered into an option agreement for the development and commercialization of MGD010. Under the terms of the agreement, MacroGenics will receive an upfront payment of $15M and Takeda receives an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.

Jury Finds for Takeda in Diabetes Drug Case

May 23, 2014 8:07 am | News | Comments

Today's verdict marks the fifth win for Takeda out of six ACTOS (pioglitazone HCL) trials. Takeda is challenging the ruling in the sixth case.                  

FDA Approves Takeda's Entyvio

May 21, 2014 7:59 am | News | Comments

Takeda Pharmaceuticals U.S.A., Inc., today announced that the FDA simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

Advertisement

Court: Misleading Campaign Ad Wasn't Defamatory

May 16, 2014 2:23 pm | by RYAN J. FOLEY, Associated Press | News | Comments

A state senator cannot sue for defamation over a rival's campaign ad that misleadingly suggested he sold dangerous drugs to children, the Iowa Supreme Court ruled Friday in a case that could have implications for politics nationwide.    

Jury Finds for Takeda in Diabetes Drug Case

May 16, 2014 9:22 am | News | Comments

Takeda Pharmaceuticals U.S.A. announced that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois and is the fifth ACTOS (pioglitazone HCl) case to reach trial.

Teva and Takeda to Commercialize Rasagiline for Parkinson’s Disease Treatment in Japan

April 28, 2014 8:18 am | News | Comments

Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan.

Takeda Names GSK Exec COO

December 2, 2013 8:47 am | News | Comments

Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.

Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR

September 13, 2013 8:20 am | News | Comments

Takeda Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. market.

Advertisement

Takeda Launches New Subsidiary in Peru

August 22, 2013 9:34 am | News | Comments

Takeda Pharmaceuticals International GmbH today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Sucampo Receives $10M Milestone Payment from Takeda on First Sale of AMITIZA®

June 27, 2013 8:14 am | News | Comments

Sucampo Pharmaceuticals, Inc. (SPI) today announced that it has received a $10 million milestone payment from Takeda Pharmaceutical Company Limited (Takeda), pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA ® (lubiprostone) in the United States for the treatment of opioid-induced constipation (OIC) in adult patient.

Boss Talk Asia: Takeda’s Yasuchika Hasegawa

June 20, 2013 8:39 am | Videos | Comments

Takeda Pharmaceutical Company’s Chief Executive Officer Yasuchika Hasegawa talks to the Wall Street Journal about his management style and “Takeda-ism” – the corporate philosophy that has led Takeda to becomeJapan’s biggest pharmaceutical manufacturer.

Doctor’s Doubts Imperil A Lucrative Diabetes Drug

May 31, 2013 8:05 am | by By ANDREW POLLACK; New York Times News Service | News | Comments

Dr. Peter C. Butler initially declined a request by the drugmaker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats.  “I said, I’m not interested in your money, go away,” Butler recalled. Merck no doubt now wishes it had.

Amag Slumps on Ferahame Recall in Switzerland

May 23, 2013 8:43 am | News | Comments

Amag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland. Amag said four patients experienced severe allergic reactions to the drug, and one of those patients died. That batch was sold only in Switzerland, and the recall doesn't affect any other countries.

Takeda to Acquire Inviragen, Inc.

May 8, 2013 8:04 am | News | Comments

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.

Takeda Launches New Subsidiary in Ecuador

March 21, 2013 7:56 am | News | Comments

Takeda Pharmaceuticals International GmbH, today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador.

Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey

March 4, 2013 7:59 am | News | Comments

More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

February 28, 2013 7:56 am | News | Comments

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

Amgen Rises on Recall of Affymax Anemia Drug

February 26, 2013 8:07 am | News | Comments

Shares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients. Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it.

Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection

February 25, 2013 7:51 am | News | Comments

Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.

Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals

February 8, 2013 7:55 am | News | Comments

Sucampo Pharmaceuticals, Inc. today announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Anchen Pharmaceuticals, Inc., Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading